Myeloproliferative Neoplasms (eBook)

The discovery of the JAK2 V617F mutation in the majority of patients with bcr/abl-negative myeloproliferative neoplasms has stimulated a number of questions regarding the diagnosis, prognosis, and treatment of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. This book provides evidence-based reviews and expert consensus results concerning the key clinical issues for patient management. Practical recommendations are provided for the optimization and standardization of management of all three types of myeloproliferative neoplasm. Risk stratification, treatment goals, and first- and second-line therapies are discussed in detail, and other relevant diagnostic and research issues are also addressed. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.

Biology: UpdateDo we need biology studies for patient management?Gerneral Issues in the Management of MPNs:Critical Issues about the Diagnosis of MPNsPatient's Information and Examinations Needed before Planning Therapy Specific Issues of Treatment in PV and ET:Risk classificationGoal of TherapyFirst-line Therapy and Monitoring the Response in the Individual PatientPrimary and Secondary Antithrombotic ProphylaxisWhen to change Therapy: Second Line OptionsThe Evolution in Myelofibrosis and LeukemiaTreatment of PMF:Current Clinical NeedsRisk StratificationGoal of Therapy: Palliation and CurativeResearch Issues and Perspectives:New drugsOngoing Clinical TrialsHow to Design Clinical Studies in Rare Diseases